References
- Barth SW, Briviba K, Watzl B, Jäger N, Marko D, Esselen M. (2010). In vivo bioassay to detect irinotecan-stabilized DNA/topoisomerase I complexes in rats. Biotechnol J, 5, 321–327.
- Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, Giordano I, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Brown KK, Lewis CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND, Gwynn MN. (2010). Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature, 466, 935–940.
- Boege F, Straub T, Kehr A, Boesenberg C, Christiansen K, Andersen A. (1996). Selected novel flavones inhibit the DNA binding or the DNA relegation step of eukaryotic topoisomerase I. J Biol Chem, 271 (4): 2262–2270.
- Bugreev DV, Nevinsky GA. (2009). Structure and mechanism of action of type IA DNA topoisomerases. Biochemistry (Mosc), 74, 1467–1481.
- Dhulipala VC, Hanumegowda UM, Balasubramanian G, Reddy CS. (2004). Relevance of the palatal protein kinase A pathway to the pathogenesis of cleft palate by secalonic acid D in mice. Toxicol Appl Pharmacol, 194, 270–279.
- Eng WK, Faucette L, Johnson RK, Sternglanz R. (1988). Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol, 34, 755–760.
- Ganesh B, Chada SR. (2000). Novel mechanism of protein kinase C inhibition involving the pseudosubstrate region by secalonic acid D in vitro. Toxicol Appl Pharmacol, 163, 86–93.
- García-Estrada C, Prada CF, Fernández-Rubio C, Rojo-Vázquez F, Balaña-Fouce R. (2010). DNA topoisomerases in apicomplexan parasites: Promising targets for drug discovery. Proc Biol Sci, 277, 1777–1787.
- Hee JC, Mi JJ, Sangwook W, Jungsook K, Eung SL, Youngjoo K, Younghwa N. (2010). New benzoxanthone derivatives as topoisomerase inhibitors and DNA cross-linkers. Bioorg Med Chem, 18, 1010–1017.
- Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C. (1999). Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience. Oncology, 56, 1–12.
- Ma J, Jones SH, Marshall R, Wu X, Hecht SM. (2005). DNA topoisomerase I inhibitors from Rinorea anguifera. Bioorg Med Chem Lett, 15, 813–816.
- Pommier Y, Leo E, Zhang H, Marchand C. (2010). DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 17 (5): 421–33.
- Raymond A, George B, Brunhilde K, Arnold LD. (1977). Secalonic acid D and F are toxic metabolites of Aspergillus aculeatus. J Org Chem, 42, 352–353.
- Ren H, Tian L, Gu Q, Zhu W. (2006). Secalonic acid D; A cytotoxic constituent from marine lichen-derived fungus Gliocladium sp. T31. Arch Pharm Res, 29, 59–63.
- Steyn PS. (1970). The isolation, structure and absolute configuration of secalonic acid D, the toxic metabolite of Penicillium oxalicum. Tetrahedron, 26, 51–57.
- Tazi J, Bakkour N, Soret J, Zekri L, Hazra B, Laine W, Baldeyrou B, Lansiaux A, Bailly C. (2005). Selective inhibition of topoisomerase I and various steps of spliceosome assembly by diospyrin derivatives. Mol Pharmacol, 67, 1186–1194.
- Topcu Z, Castora FJ. (1995). Mammalian mitochondrial DNA topoisomerase I preferentially relaxes supercoils in plasmids containing specific mitochondrial DNA sequences. Biochim Biophys Acta, 1264, 377–387.
- Webb MR, Ebeler SE. (2004). Comparative analysis of topoisomerase IB inhibition and DNA intercalation by flavonoids and similar compounds: Structural determinates of activity. Biochem J, 384, 527–541.
- Zhang W, Krohn K, Flörke U, Pescitelli G, Di Bari L, Antus S, Kurtán T, Rheinheimer J, Draeger S, Schulz B; Zia-Ullah. (2008). New mono- and dimeric members of the secalonic acid family: Blennolides A-G isolated from the fungus Blennoria sp.. Chemistry, 14, 4913–4923.